WallStSmart

Baidu Inc (BIDU)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 139% more annual revenue ($309.06B vs $129.08B). NVO leads profitability with a 33.1% profit margin vs 4.3%. BIDU appears more attractively valued with a PEG of 0.66. NVO earns a higher WallStSmart Score of 55/100 (C).

BIDU

Hold

46

out of 100

Grade: D+

Growth: 4.7Profit: 4.0Value: 4.7Quality: 7.0
Piotroski: 2/9Altman Z: 2.40

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BIDUSignificantly Overvalued (-1147.8%)

Margin of Safety

-1147.8%

Fair Value

$11.63

Current Price

$115.60

$103.97 premium

UndervaluedFair: $11.63Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIDU2 strengths · Avg: 9.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

BIDU4 concerns · Avg: 3.0/10
Return on EquityProfitability
1.9%3/10

ROE of 1.9% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Operating MarginProfitability
4.5%3/10

Operating margin of 4.5%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BIDU

The strongest argument for BIDU centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : BIDU

The primary concerns for BIDU are Return on Equity, Profit Margin, Operating Margin. A P/E of 65.8x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

BIDU profiles as a value stock while NVO is a declining play — different risk/reward profiles.

BIDU carries more volatility with a beta of 0.39 — expect wider price swings.

BIDU is growing revenue faster at -4.1% — sustainability is the question.

BIDU generates stronger free cash flow (88M), providing more financial flexibility.

Bottom Line

NVO scores higher overall (55/100 vs 46/100), backed by strong 33.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baidu Inc

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · China

Baidu, Inc. provides Internet search services primarily in China. The company is headquartered in Beijing, China.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?